Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay M Young

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|October 22, 2002
VardenafilJay M Young
Urology|August 30, 2003
Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroupsHartmut Porst, Jay M Young, Abraham C Schmidt, et al.
Urology|November 5, 2002
Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American menJay M Young, Carol Bennett, Patricia Gilhooly, et al.
Diabetes Care|March 1, 2003
Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose studyIrwin Goldstein, Jay M Young, Jerome Fischer, et al.
The Journal of Urology|February 14, 2007
Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trialKevin T McVary, William Monnig, Joseph L Camps, et al.
Mayo Clinic Proceedings|October 11, 2005
Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled studyLuc Valiquette, Jay M Young, Ignacio Moncada, et al.
The Journal of Urology|March 27, 2007
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasiaKevin T McVary, Claus G Roehrborn, Jed C Kaminetsky, et al.
Journal of Andrology|May 4, 2005
Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trialJay M Young, Robert A Feldman, Stephen M Auerbach, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 2, 2012
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patientsEdward Messing, Jason R Gee, Daniel R Saltzstein, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|October 22, 2002
VardenafilJay M Young
Urology|August 30, 2003
Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroupsHartmut Porst, Jay M Young, Abraham C Schmidt, et al.
Urology|November 5, 2002
Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American menJay M Young, Carol Bennett, Patricia Gilhooly, et al.
Diabetes Care|March 1, 2003
Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose studyIrwin Goldstein, Jay M Young, Jerome Fischer, et al.
The Journal of Urology|February 14, 2007
Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trialKevin T McVary, William Monnig, Joseph L Camps, et al.
Mayo Clinic Proceedings|October 11, 2005
Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled studyLuc Valiquette, Jay M Young, Ignacio Moncada, et al.
The Journal of Urology|March 27, 2007
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasiaKevin T McVary, Claus G Roehrborn, Jed C Kaminetsky, et al.
Journal of Andrology|May 4, 2005
Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trialJay M Young, Robert A Feldman, Stephen M Auerbach, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 2, 2012
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patientsEdward Messing, Jason R Gee, Daniel R Saltzstein, et al.
Pageof 1